DOFETILIDE PACKAGE INSERT PDF

(dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in. Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide).

Author: Kajigis Daijas
Country: Moldova, Republic of
Language: English (Spanish)
Genre: Sex
Published (Last): 2 July 2016
Pages: 71
PDF File Size: 14.15 Mb
ePub File Size: 20.57 Mb
ISBN: 769-9-94598-121-7
Downloads: 66190
Price: Free* [*Free Regsitration Required]
Uploader: Vudolrajas

Med Clin N Am Clinical Electrophysiology web site. Elsevier About ScienceDirect Remote access Shopping cart Contact and support Terms and dofehilide Privacy policy We use cookies to help provide and enhance our service and tailor content and ads. Circ Arrhythm Electrophysiol 8: ECG was obtained before the initiation of therapy and 2 h after each dose and was monitored for QT interval prolongation. All patients were adequately anticoagulated prior to initiating dofetilide and were placed on continuous cardiac telemetry.

All Interactions with Dofetilide

In large-scale population studies, AF has been associated with adverse cardiovascular events, including thromboembolism, heart failure, sudden cardiac death, and cardiovascular mortality 4—6. Am J Med Dofetilide was started during a h inpatient hospitalization per standard protocol Two patients with a normal baseline QTc developed VT after the second dose.

Dofetilide dosing was based pacakge glomerular filtration rate GFR: Dofetilide initiation protocol Dofetilide was started during a h inpatient hospitalization per standard protocol The incidence of QT prolongation or VT that lead to discontinuation of dofetilide is remarkably higher in the real-world setting than in clinical trials. Methods Study patients We conducted a dogetilide cohort study of consecutive patients hospitalized for starting dofetilide to treat AF at the Minneapolis Veterans Affairs Health Care System from to Patients who were taking concomitant QT-prolonging drugs were 1.

Abstract Objectives The purpose of this study was to determine the incidence and correlates of QT prolongation or ventricular tachycardia VT resulting in discontinuation of dofetilide in a real-world setting.

Related Posts  CADENA TROFICA DOWNLOAD

Dofetilide – GlobalRPH

Patients who were taking concomitant QT-prolonging drugs were 1. Although it is ideal to stop or replace these medications with alternatives when starting dofetilide, it is not always possible. Am J Psychiatry[E-pub ahead of print]. JI Intervent Cardiac Electrophysiol Outcomes packge Citalopram dose-risk mitigation in a veteran population. To our knowledge, this is pqckage one of the few studies study assessing the incidence and predictors of discontinuation of dofetilide in a real-world, inpatient setting.

View inline View popup. In these patients, it may be necessary to consider ablation or alternate medical therapies early in the management of AF.

Dofetilide (Tikosyn)

GFR glomerular filtration rate. There were no other differences between patients who discontinued versus those who were discharged on dofetilide. Conclusions The incidence of QT prolongation or VT that lead to discontinuation of dofetilide is remarkably higher in the real-world setting than in clinical trials.

Abbreviations and Acronyms AF atrial fibrillation. Download high-res image 99KB Download full-size image. Article Versions You are currently viewing a previous version of this article July 27, – Conclusions These data indicate that the incidence of dofetilide discontinuation because of QT dofetolide or VT in a real-world setting is remarkably higher than that reported in clinical trials.

Of these 8 patients, 1 The primary outcome variable was the discontinuation of ineert because of QTc prolongation or VT. Concomitant use of other QT-prolonging drugs was the only significant predictor of discontinuation of dofetilide.

These results suggest that the incidence of discontinuation of dofetilide because of adverse events is much higher in a real-world setting than has been reported in clinical trials. Dofetilide is a class III antiarrhythmic agent approved for achieving and maintaining sinus rhythm in patients with symptomatic atrial fibrillation.

However, neither study examined the factors associated with the discontinuation of dofetilide Skip to main content. QT interval prolongation occurs because of congenital and acquired abnormalities, with acquired causes being much more prevalent. Neither study reported information on the concomitant use of QTc-prolonging drugs. Dofetilide, a class III antiarrhythmic drug, is frequently used for rhythm control in patients with AF. The rate of dofetilide discontinuation remained high in dotetilide subgroup of patients who had normal QTc at baseline and were not taking concomitant hydrochlorothiazide.

Related Posts  RESEALED ERYTHROCYTES EPUB DOWNLOAD

Am J Cardiol Objectives The purpose of this study was to determine the incidence and correlates of QT prolongation or ventricular tachycardia VT resulting in discontinuation of dofetilide in a real-world setting. This study was approved by the institutional review board and the Research and Development Committee at our institution. Dofeilide comparison to patients who were taking no other QT-prolonging medications, the odds of dofetilide discontinuation was 1.

In symptomatic patients with AF, antiarrhythmic therapy can be useful to achieve and dofftilide normal sinus rhythm to alleviate symptoms and optimize heart failure management 7— Concomitant use of other QT-prolonging drugs was associated with discontinuation of dofetilide. The majority of the concomitant QT-prolonging drugs in this study were antidepressants. View the most recent version of this article. Footnotes The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Food and Drug Administration because of concerns about QT prolongation and sudden death.

American College of Cardiology Foundation. Background Dofetilide is a class III antiarrhythmic agent approved for achieving and maintaining sinus rhythm in patients with symptomatic atrial fibrillation. Conclusions The incidence of QT prolongation or VT that lead to discontinuation of dofetilide is remarkably higher in the real-world setting than in clinical trials. Under an Elsevier user license.